Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking Union Medical College
- Trial code
- NCT06926192
- Record updated
- 16 April 2025
- Original description
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.Read full original descriptionShow less
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.
Inclusion: Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS; The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital; Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital; Patients with complete clinical data followed up for at least 1 year.
Exclusion: Patients who received additional adjuvant therapy during the follow-up period; Patients lost to follow-up; Patients with less than one year of follow-up.